Q3 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q3 2025 earnings per share estimates for Illumina in a research note issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings per share of $1.05 for the quarter, down from their previous forecast of $1.06. The consensus estimate for Illumina's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina's Q4 2025 earnings at $1.40 EPS, Q1 2026 earnings at $0.91 EPS and FY2027 earnings at $5.20 EPS.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. During the same quarter last year, the firm earned $0.98 earnings per share. The business's revenue for the quarter was down 1.4% on a year-over-year basis.

ILMN has been the subject of several other research reports. Citigroup cut Illumina from a "hold" rating to a "strong sell" rating and cut their price target for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. Guggenheim cut their target price on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Morgan Stanley cut their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. Stephens reissued an "overweight" rating and set a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Finally, Scotiabank cut Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price for the company. in a research note on Friday, July 11th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $125.11.

Illumina Price Performance

NASDAQ:ILMN opened at $96.14 on Monday. Illumina has a one year low of $68.70 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. The stock has a market cap of $15.22 billion, a PE ratio of -15.84, a P/E/G ratio of 1.88 and a beta of 1.36. The stock has a 50 day moving average price of $89.22 and a 200 day moving average price of $94.68.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Pure Financial Advisors LLC purchased a new position in Illumina in the second quarter valued at $434,000. Institute for Wealth Management LLC. purchased a new position in Illumina in the second quarter valued at $213,000. Generali Investments CEE investicni spolecnost a.s. boosted its holdings in Illumina by 33.3% in the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 6,000 shares of the life sciences company's stock valued at $572,000 after purchasing an additional 1,500 shares during the period. PGGM Investments boosted its holdings in Illumina by 115.1% in the second quarter. PGGM Investments now owns 1,149,408 shares of the life sciences company's stock valued at $109,665,000 after purchasing an additional 614,973 shares during the period. Finally, Truist Financial Corp boosted its holdings in Illumina by 3.8% in the second quarter. Truist Financial Corp now owns 50,004 shares of the life sciences company's stock valued at $4,771,000 after purchasing an additional 1,850 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Illumina

In other news, CFO Ankur Dhingra purchased 6,100 shares of the stock in a transaction dated Monday, May 12th. The stock was acquired at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer directly owned 24,906 shares in the company, valued at approximately $2,022,616.26. This represents a 32.44% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 0.17% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.